CD22

Tallac Presents First Clinical Data for TAC-001 at SITC 2023

Retrieved on: 
Friday, November 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, PD, CD22, Mount Tallac, TLR9, Poster, Multimedia, SITC, Immunotherapy, Immunity, MOA, RECIST, Melanoma, Immunology, Cancer, Therapy, Partial agonist, TRAAC, Vaccine, Pharmaceutical industry, Pharmacokinetics

“These TAC-001 clinical data provide evidence that systemic administration of a TLR9 immune agonist targeting and activating B cells is generally well tolerated and induces immune activation consistent with preclinical studies.

Key Points: 
  • “These TAC-001 clinical data provide evidence that systemic administration of a TLR9 immune agonist targeting and activating B cells is generally well tolerated and induces immune activation consistent with preclinical studies.
  • TAC-003 has completed pre-clinical testing, including exploratory toxicological studies in cynomolgus monkeys, and has been selected as the Company’s third clinical candidate.
  • “We are excited to see these initial clinical data with TAC-001, the first program from Tallac’s TRAAC platform,” said Dr. Hong I. Wan, president, CEO and co-founder of Tallac Therapeutics.
  • Tallac Therapeutic’s TRAAC platform is designed to deliver a potent and differentiated TLR9 agonist (T-CpG) for targeted immune activation via systemic administration.

Florida Cancer Specialists & Research Institute Physicians Contribute to Immunotherapy Treatment Advances at Global Meeting

Retrieved on: 
Friday, November 3, 2023
Drug development, Science, Patient, Trial of the century, Education, PD, Nivolumab, Hope, Pembrolizumab, Physician, CD22, MD, HPK1, Research, INT, Immunotherapy, ADC, FIH, Disease, Immune system, Safety, Society, Cancer, FCS, T cell, Vaccine, Pharmaceutical industry, Pharmacokinetics

FORT MYERS, Fla., Nov. 3, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute (FCS) physicians will present at the Society for Immunotherapy of Cancer Annual Meeting this week in San Diego.

Key Points: 
  • FORT MYERS, Fla., Nov. 3, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute (FCS) physicians will present at the Society for Immunotherapy of Cancer Annual Meeting this week in San Diego.
  • They will join stakeholders across the immune-oncology field worldwide to advance the science, discover breakthroughs and enhance education on cancer immunotherapy, which uses the body's own immune system to find, target and fight many forms of the disease.
  • "Immunotherapy is one of the most promising and successful treatment areas for cancer, even at the most advanced stages, said Lucio N. Gordan, MD , FCS President & Managing Physician.
  • "Through our robust and far-reaching clinical trials research program, FCS continues to contribute to cutting-edge research that is providing hope and improving outcomes for cancer patients worldwide."

CARGO Therapeutics Announces Appointment of Ginna Laport, MD, as Chief Medical Officer

Retrieved on: 
Tuesday, October 17, 2023
University, Stanford Cancer Institute, Antibody, Monoclonal antibody, Division, Drug, Research, Trial of the century, Stanford University School of Medicine, MD, Mosunetuzumab, BLA, IND, Health, Biotechnology, Medicine, Disease, Cancer, Patient, BA, Therapy, B-cell lymphoma, CAR, NME, CD22, Publication, SAN, CD19, BMT, Acceleration, Baylor University, B Division (New York City Subway), NIH, Pharmaceutical industry, Nursing, Stanford University, Blood

SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer. Dr. Laport is a seasoned biotechnology executive and senior clinical leader. She will serve on the Company’s executive team and will be responsible for providing leadership and direction to guide CARGO’s clinical development strategy and execution, including the advancement of CARGO’s lead candidate, CRG-022, as well as its pipeline of next-generation CAR T-cell therapies for cancer patients. CRG-022 is an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, currently in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.

Key Points: 
  • SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer.
  • “We are thrilled to announce the addition of Ginna to our team as Chief Medical Officer.
  • With her extensive leadership background in clinical drug development, particularly in hematology/oncology, she brings invaluable expertise to our organization,” said Gina Chapman, CARGO’s President and Chief Executive Officer.
  • Previously, Dr. Laport was Chief Medical Officer at Tempest Therapeutics, where she directed the clinical development of small molecules that combine both tumor-targeted and immune-mediated mechanisms, including several IND submissions.

Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood

Retrieved on: 
Tuesday, September 5, 2023
Antigen, B-cell lymphoma, CD19, Blood, CD22, MRD, CAR, Cytokine release syndrome, Patient, B-ALL, EFS, European Society for Medical Oncology, Therapy, Blinatumomab, Disease, Pharmaceutical industry, Vaccine

CD19 negative relapse is a major cause of treatment failure after CD19 CAR T cell therapy for pediatric B-ALL.

Key Points: 
  • CD19 negative relapse is a major cause of treatment failure after CD19 CAR T cell therapy for pediatric B-ALL.
  • AUTO1/22 maintained the safety profile of obe-cel alone, with no cases of severe cytokine release syndrome.
  • This includes 2 (of 3) patients who had CD19 negative disease, demonstrating the efficacy of the CD22 CAR.
  • “CAR T-cell therapies which co-target CD19 and CD22 are needed to prevent antigen-negative escape in pediatric B-ALL.

ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, August 8, 2023
Mitsubishi Tanabe Pharma, Workforce, Biologics license application, Institutional review board, Rituximab, Medicare (United States), DLBCL, KAAG1, Infrastructure Investment and Jobs Act, IDMC, Medicare Part D, Overland, CD22, G&A, NSCLC, Lung cancer, EDT, Sale, IHC, Medicare, Sarcoma, PIN, Group purchasing organization, AXL, IRB, Patient, Investment, European, National Medical Products Administration, Immunohistochemistry, Growth, ADC, GPO, FDA, S&M, Therapy, MD Anderson Cancer Center, NYSE, BLA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, NMPA, Video game, Fine chemical, Pharmaceutical industry, Reinsurance, EU

LAUSANNE, Switzerland, Aug. 08, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter 2023 and provided business updates.

Key Points: 
  • We look forward to keeping you updated on our progress.”
    ZYNLONTA generated net sales of $19.2 million in the second quarter of 2023, representing an 11% increase over the second quarter of 2022.
  • The Company’s partner Sobi completed the first European commercial sale of ZYNLONTA with the launch in Germany in the second quarter of 2023.
  • R&D expenses were $31.9 million for the quarter ended June 30, 2023, compared to $48.5 million for the same quarter in 2022.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss second quarter 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time.

Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, August 3, 2023
Amgen, CD19, Senior, Diabetes, IL-7, ISSCR, Biogen, Hosting, Janssen, GAAP, Autoimmunity, Research and development, Development, Patient, Data, Transplant, Bone marrow, Therapy, Vertex, CD22, Organization, HIP, Genetic, Neoplasm, SANA, IND, Safety, Abstract, AACR, Biotechnology, Contingency, Lymphoid leukemia, Seagen, Cell, CAR, Administration, Immune system, Science Translational Medicine, Escape Room, Sana, Drug development, Nature Communications, Drug, Person, State Administrative Expenses, Organoid, Nature Biotechnology, NHP, Recurrence, Immunosuppression, BCMA, Vaccine, Pharmaceutical industry, Nursing, Dentistry, Cryptocurrency, Reinsurance, Merck, Research

Sana is developing SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes.

Key Points: 
  • Sana is developing SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes.
  • Sana expects initial data later this year from an investigator-sponsored trial transplanting hypoimmune-modified primary human islet cells into type 1 diabetes patients.
  • Second, Sana created a humanized mouse model with immune cells from a diabetic person and transplanted pancreatic islet cells derived from the diabetic person’s stem cells.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Enterome's new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma

Retrieved on: 
Wednesday, June 14, 2023
Molecular mimicry, Rituximab, CD20, ICML, Lenalidomide, Lymphoma, CD268, CD22, Adrenal tumor, Immunotherapy, Glioblastoma, Trial of the century, Protein, CD8, Asilomar International Conference on Climate Intervention Technologies, Patient, Standard of care, Colorectal cancer, Epitope, Neoplasm, Poster, Lymphocyte, CD37, Safety, BAFF, UCP2, Conference, Peptide, Inflammation, Vaccine, Pharmaceutical industry

EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimic™ peptides.

Key Points: 
  • EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimic™ peptides.
  • These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the B lymphocyte-specific lineage markers CD20, CD22, CD37 and CD268 (BAFF receptor).
  • The unique ability of EO2463 immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes that are abundant in iNHL.
  • We are also preparing to enter another new OncoMimics™ candidate, EO4010, for the treatment of metastatic colorectal cancer, into clinical development.”

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event

Retrieved on: 
Monday, June 5, 2023
Graft-versus-host disease, HD, Antigen, DNA, BP, TRAC, HSPC, Euronext Growth, Interferon gamma, UGI, CD19, Red blood cell, ISCT, Lymphoid leukemia, CD20, Neoplasm, Thymine, Patient derived xenograft, Survival, Gene editing, Bone marrow, CD52, CD22, Deamination, Toxicity, Cell, Stem cell, PDX, CAR, Patient, Risk, Engineering, International Society, Knowledge, HBB, TALEN, TC, Phenotype, Vaccine, Online shopping, Cosmetics, HBSS, Cellectis, Cytosine

The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.

Key Points: 
  • The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.
  • UCART20x22 is Cellectis’ first dual-targeting, allogeneic cell therapy product candidate targeting CD20 and CD22, to address the current challenges in the treatment of B-cell malignancies.
  • The oral presentation highlighted the following preclinical data:
    Robust in vitro and in vivo cytolytic activity against tumors expressing different antigen combinations.
  • The oral presentation is available on Cellectis’ website: https://www.cellectis.com/en/investors/scientific-presentations/
    Sickle cell disease stems from a single point mutation in the HBB gene which results in sickle hemoglobin.

Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies

Retrieved on: 
Wednesday, May 31, 2023
Graft-versus-host disease, Antigen, TRAC, Euronext Growth, CD19, Lymphoid leukemia, CD20, Neoplasm, CD52, Bone marrow, CD22, Attention, PDX, CAR, Death, Cancer Immunology Research, Animal, Patient, Risk, Mantle cell lymphoma, Cancer, Research, Vaccine, Cellectis

To address these challenges, Cellectis developed UCART20x22, its first allogeneic dual CAR T-cell product candidate targeting two validated antigens commonly expressed in B-cell malignancies, CD20 and CD22, and whose expression is preserved after CD19 CAR T-cell treatment.

Key Points: 
  • To address these challenges, Cellectis developed UCART20x22, its first allogeneic dual CAR T-cell product candidate targeting two validated antigens commonly expressed in B-cell malignancies, CD20 and CD22, and whose expression is preserved after CD19 CAR T-cell treatment.
  • Moreover, UCART20x22 is developed to be available off-the-shelf and to offer a solution for patients whose T-cells are not functional or for which autologous manufacturing fails.
  • UCART20x22 is Cellectis’ first product candidate fully designed, developed and manufactured in-house at Cellectis.
  • This article is available on Cancer Immunology Research website by clicking on this link: https://aacrjournals.org/cancerimmunolres/article/doi/10.1158/2326-6066....

CARGO Therapeutics to Present at the Jefferies Global Healthcare Conference 

Retrieved on: 
Wednesday, May 31, 2023
Clinical trial, CAR, Cancer, CD22, Therapy, SAN, Eastern Time Zone, Vaccine, Pharmaceutical industry

SAN MATEO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced that management will present at the upcoming Jefferies Global Healthcare Conference on Friday, June 9, 2023 at 9:00 a.m. Eastern Time in New York City.

Key Points: 
  • SAN MATEO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced that management will present at the upcoming Jefferies Global Healthcare Conference on Friday, June 9, 2023 at 9:00 a.m. Eastern Time in New York City.
  • CARGO is advancing an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy as well as a pipeline of next generation CAR T-cell therapies for cancer using its proprietary cell engineering platform technologies.
  • The Company's lead clinical candidate, CRG-022, is preparing to enter a pivotal Phase 2 clinical trial in 2023.